226 related articles for article (PubMed ID: 25203866)
1. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
[TBL] [Abstract][Full Text] [Related]
2. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
Lim WS; Tardi PG; Xie X; Fan M; Huang R; Ciofani T; Harasym TO; Mayer LD
Leuk Lymphoma; 2010 Aug; 51(8):1536-42. PubMed ID: 20528246
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
[TBL] [Abstract][Full Text] [Related]
4. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
[TBL] [Abstract][Full Text] [Related]
5. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
6. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
[TBL] [Abstract][Full Text] [Related]
7. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD; Tardi P; Louie AC
Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.
Feldman EJ; Kolitz JE; Trang JM; Liboiron BD; Swenson CE; Chiarella MT; Mayer LD; Louie AC; Lancet JE
Leuk Res; 2012 Oct; 36(10):1283-9. PubMed ID: 22840315
[TBL] [Abstract][Full Text] [Related]
9. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
11. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
[TBL] [Abstract][Full Text] [Related]
13. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
[TBL] [Abstract][Full Text] [Related]
14. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
Asghari H; Lancet J
Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
[TBL] [Abstract][Full Text] [Related]
15. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.
Bayne WF; Mayer LD; Swenson CE
J Pharm Sci; 2009 Jul; 98(7):2540-8. PubMed ID: 19009594
[TBL] [Abstract][Full Text] [Related]
17. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
18. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals.
Wang Q; Tardi P; Sadowski N; Xie S; Heller D; Mayer L
Nanomedicine; 2020 Nov; 30():102275. PubMed ID: 32750494
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y;
Int J Hematol; 2024 Mar; ():. PubMed ID: 38532078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
